Literature DB >> 25831967

Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors).

Stephen M Stahl.   

Abstract

Vortioxetine is an antidepressant that targets multiple pharmacologic modes of action at sites--or nodes--where serotonergic neurons connect to various brain circuits. These multimodal pharmacologic actions of vortioxetine lead to enhanced release of various neurotransmitters, including serotonin, at various nodes within neuronal networks.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25831967     DOI: 10.1017/S1092852915000139

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  14 in total

Review 1.  Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature.

Authors:  William M Greenberg; Leslie Citrome
Journal:  Clin Pharmacokinet       Date:  2017-05       Impact factor: 6.447

Review 2.  "Novel Psychopharmacology for Depressive Disorders".

Authors:  Michele Fornaro; Domenico De Berardis; Annalisa Anastasia; Andrea Fusco
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  Randomized Controlled Trials of Add-On Antidepressants in Schizophrenia.

Authors:  Viacheslav Terevnikov; Grigori Joffe; Jan-Henry Stenberg
Journal:  Int J Neuropsychopharmacol       Date:  2015-05-19       Impact factor: 5.176

Review 4.  The serotonergic system and cognitive function.

Authors:  Dubravka Švob Štrac; Nela Pivac; Dorotea Mück-Šeler
Journal:  Transl Neurosci       Date:  2016-05-09       Impact factor: 1.757

Review 5.  Zinc in the Monoaminergic Theory of Depression: Its Relationship to Neural Plasticity.

Authors:  Urszula Doboszewska; Piotr Wlaź; Gabriel Nowak; Maria Radziwoń-Zaleska; Ranji Cui; Katarzyna Młyniec
Journal:  Neural Plast       Date:  2017-02-19       Impact factor: 3.599

Review 6.  Vortioxetine: Clinical Pharmacokinetics and Drug Interactions.

Authors:  Grace Chen; Astrid-Maria Højer; Johan Areberg; George Nomikos
Journal:  Clin Pharmacokinet       Date:  2018-06       Impact factor: 6.447

Review 7.  Cognitive impairment in depression: recent advances and novel treatments.

Authors:  Giulia Perini; Matteo Cotta Ramusino; Elena Sinforiani; Sara Bernini; Roberto Petrachi; Alfredo Costa
Journal:  Neuropsychiatr Dis Treat       Date:  2019-05-10       Impact factor: 2.570

8.  When the drugs don't work: treatment-resistant schizophrenia, serotonin and serendipity.

Authors:  Penelope Lowe; Amir Krivoy; Lilla Porffy; Erna Henriksdottir; Whiskey Eromona; Sukhwinder S Shergill
Journal:  Ther Adv Psychopharmacol       Date:  2017-11-02

9.  An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder.

Authors:  Anish Shah; Joanne Northcutt
Journal:  Ann Gen Psychiatry       Date:  2018-05-11       Impact factor: 3.455

10.  Tolerability and efficacy of vortioxetine versus SSRIs in elderly with major depression. Study protocol of the VESPA study: a pragmatic, multicentre, open-label, parallel-group, superiority, randomized trial.

Authors:  Giovanni Ostuzzi; Chiara Gastaldon; Angelo Barbato; Barbara D'Avanzo; Mauro Tettamanti; Igor Monti; Andrea Aguglia; Eugenio Aguglia; Maria Chiara Alessi; Mario Amore; Francesco Bartoli; Massimo Biondi; Paola Bortolaso; Camilla Callegari; Giuseppe Carrà; Rosangela Caruso; Simone Cavallotti; Cristina Crocamo; Armando D'Agostino; Pasquale De Fazio; Chiara Di Natale; Laura Giusti; Luigi Grassi; Giovanni Martinotti; Michela Nosé; Davide Papola; Marianna Purgato; Alessandro Rodolico; Rita Roncone; Lorenzo Tarsitani; Giulia Turrini; Elisa Zanini; Francesco Amaddeo; Mirella Ruggeri; Corrado Barbui
Journal:  Trials       Date:  2020-08-03       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.